Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16867691 | 0.82 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16868190 | 0.81 | PDE2A (0.59) | PDE2A | |
| SCHEMBL16867689 | 0.74 | PDE2A (1.00) | PDE2A | |
| SCHEMBL16867669 | 0.72 | PDE2A (0.62) | PDE2A | |
| SCHEMBL404601 | 0.65 | KDM4E (0.56) | — | |
| SCHEMBL403588 | 0.64 | PDE5A (0.53) | PDE2A | |
| SCHEMBL403796 | 0.63 | PDE5A (0.64) | PDE2A | |
| SCHEMBL3829567 | 0.63 | CA2 (0.49) | — | |
| SCHEMBL403861 | 0.62 | RNASEH1 (0.51) | PDE2A | |
| SCHEMBL3493912 | 0.62 | MAPT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE3A | PDE2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.